1. Site-directed mutagenesis of human plasma butyrylcholinesterase has led to novel hydrolases that rapidly destroy cocaine. We are investigating whether viral gene transfer of such enzymes might reduce addiction liability by blocking cocaine from its sites of action.
2. As groundwork for a possible gene therapy, we previously studied adenoviral transduction of cocaine hydrolases in the rat. Systemically injected vectors raised plasma cocaine hydrolase activity greatly, reduced pressor responses to cocaine, and lowered cocaine's tissue burden.
3. In the present study, to reduce cocaine's brain access still further, vectors were injected directly into the nucleus accumbens. Six days later, medium sized neurons gained dramatic butyrylcholinesterase activity. Species-selective immunohistochemistry proved that the transgene accounted for this activity.
4. Since the transgene product is so efficient with cocaine as a substrate, it is now reasonable to begin testing gene therapy in rodent models of cocaine addiction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Brimijoin, S., Mintz, K. P., and Alley, M. (1983). Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase. Mol. Pharmacol. 24:513–520.
Brimijoin, S., Shen, M., and Sun, H. (2002). Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal. Biochem. 309:200–205.
Doctor, B. P. (2003). Butyrylcholinesterase: Its Use for Prophylaxis of Organophosphate Exposure. In Giacobini, E. (ed.), Butyrylcholinesterase: Its Function and Inhibitors, Martin Dunitz, London, pp. 163–177.
Gao, Y., and Brimijoin, S. (2004). An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J. Pharmacol. Exp. Ther. 310:1046–1052.
Gao, Y., Atanasova, E., Nan, S., Pancook, J. D., Watkins, J. D., and Brimijoin, S. (2005). Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol. 67:204–211.
Koelle, G. B., and Friedenwald, J. S. (1949). A histochemical method for localizing cholinesterase activity. Proc. Soc. Exp. Biol. Med. 70:617–622.
Li, B., Stribley, J. A., Ticu, A., Xie, W., Schopfer, L. M., Hammond, P., Brimijoin, S., Hinrichs, S., and Lockridge, O. (2000). Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem. 75:1320–1331.
McClung, C. A., and Nestler, E. J. (2003). Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat. Neurosci. 6:1208–1215.
Pancook, J. D., Pecht, G., Ader, M., Mosko, M., Lockridge, O., and Watkins, J. D. (2003). Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J. 17:A565.
Stewart, D. J., Inaba, T., Tang, B. K., and Kalow, W. (1977). Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20:1557–1564.
Sun, H., Pang, Y. P., Lockridge, O., and Brimijoin, S. (2002a). Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 621:220–224.
Sun, H., Shen, M. L., Pang, Y. P., Lockridge, O., and Brimijoin, S. (2002b). Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J. Pharmacol. Exp. Ther. 302:710–716.
ACKNOWLEDGMENT
A Mayo Distinguished Investigator Award provided financial support for this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gao, Y., Brimijoin, S. Viral Transduction of Cocaine Hydrolase in Brain Reward Centers. Cell Mol Neurobiol 26, 355–361 (2006). https://doi.org/10.1007/s10571-006-9050-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-006-9050-z